prostate cancer
J&J’s apalutamide shows strength in non-metastatic prostate cancer
February 7, 2018Research and Development J&J, JJ, Johnson & Johnson, pharma, prostate cancer
Johnson & Johnson unveiled new data at the ASCO Genitourinary Cancer symposium which demonstrated that its androgen receptor antagonist apalutamide …
UK breast cancer mortality falls 10% over five years, overtaken by prostate deaths for first time
February 5, 2018Research and Development, Sales and Marketing Cancer, Cancer Research UK, breast cancer, pharma, prostate cancer
Breast cancer deaths in the UK have fallen by 10% in the past five years, according to research released by …
Getting precision treatments over the line will be a team effort, not an individual bolt for glory
December 7, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Prostate Cancer UK, biotech, drugs, pharma, pharmaceutical, prostate cancer
We’ve finally reached the starter’s block when it comes to precision medicine approaches to prostate cancer, but Dr Matthew Hobbs, …
17,000 English patients are surviving Stage 4 cancer for two years or more, new data shows
November 8, 2017Research and Development Cancer, bladder cancer, breast cancer, colon cancer, lung cancer, pharma, prostate cancer
At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or …
Latest prostate cancer research could provide boost for J&J
June 5, 2017Research and Development, Sales and Marketing CRUK, Cancer, Johnson & Johnson, prostate cancer
Research funded by Cancer Research UK has found that abiraterone added to hormone therapy improved survival by over a third …
Cheap blood test may help tailor prostate cancer treatment
May 4, 2017Research and Development Blood test, prostate cancer
A blood test that costs less than £50 to perform could prevent men from undergoing treatment with two drugs that …
Clinical trial shows yoga negates side-effects of prostate cancer treatment
April 7, 2017Medical Communications prostate cancer, prostate treatment, yoga
Men who are treated for prostate cancer display side-effects of treatment by radiation that can often seriously disrupt their personal …
Combination immunotherapy shows promise in castration-resistant prostate cancer
March 13, 2017Research and Development, Sales and Marketing prostate cancer
Researchers at the University of Texas MD Anderson Cancer Center have found that castration-resistant prostate cancer responds well to a …
Two-decade-long prostate cancer study finds antiandrogen improves survival
February 2, 2017Research and Development antiandrogen, oncology, prostate cancer
Research conducted over the course of two decades has found a positive correlation between overall survival in prostate cancer patients …
“Biggest leap in decades” for prostate cancer, 1 in 4 could avoid biopsies
January 20, 2017Medical Communications, Research and Development Biposy, prostate cancer
A new study has estimated that one in four men could avoid unnecessary invasive biopsies to detect prostate cancer – …
Scottish Medicines Consortium approves Sanofi’s prostate cancer drug
December 12, 2016Manufacturing and Production, Sales and Marketing Jevtana, Sanofi, prostate cancer
Sanofi’s speciality care global business unit Sanofi Genzyme has announced that the Scottish Medicines Consortium has accepted the company’s Jevtana …
NICE recommends Bayer’s Xofigo for prostate cancer treatment
September 2, 2016Medical Communications, Sales and Marketing Bayer, NICE, approval, prostate cancer, recommendation, xofigo
NICE has issued final draft guidance recommending Bayer’s Xofigo (radium-223 dichloride) for the treatment of prostate cancer. Previously, the drug …
Failure in pivotal Phase III study obliterates stock at Tokai Pharmaceuticals
July 27, 2016Research and Development phase III, prostate cancer, tokai pharmaceuticals
Shares at Tokai Pharmaceuticals have been sent into freefall following the suspension of a pivotal Phase III trial for their …
Bayer, Orion to start Phase III trials for prostate cancer drug
June 3, 2016Medical Communications, Research and Development, Sales and Marketing Bayer, drug trial, orion, prostate cancer, research
German pharma and crop sciences giant Bayer (ETR: BAYN) and Orion Corp (Nasdaq Helsinki: ORNAV) have agreed to start a Phase …
NICE recommends Jevtana for advanced prostate cancer
May 25, 2016Sales and Marketing Jevtana, NICE, approval, prostate cancer, recommendation
The National Institute for Health and Care Excellence (NICE) has recommended Sanofi Genzyme’s Jevtana (cabazitaxel), in combination with prednisone or …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
